

Counsel, New York

Intellectual Property and Technology



T: 212.735.2469
kendall.ickes@skadden.com

Education

J.D., Brooklyn Law School, 2019
(*magna cum laude*)

B.S., Ohio State University, 2014

B.A., Ohio State University, 2014

Bar Admissions

New York

Kendall Ickes focuses her practice on transactional matters in the intellectual property and technology space. Ms. Ickes advises clients from a wide range of industries, including financial services and private equity, with a strong focus on matters in the health care, pharmaceuticals and biotechnology sectors. She also provides intellectual property and technology-related support on M&A and secured financing transactions.

Her significant representations include:

Life Sciences

- Alcon Inc. in its \$355 million acquisition of the U.S. commercialization rights to SIMBRINZA from Novartis AG
- Alnylam Pharmaceuticals, Inc. in its \$2.8 billion co-development and co-commercialization agreement with Roche Holding AG to develop and commercialize its hypertension drug Zilebesiran
- Catalent, Inc. in its acquisition by Novo Holdings, the holding and investment company for the Novo Nordisk Foundation, at an enterprise value of \$15.5 billion
- CerSci Therapeutics, Inc. in its acquisition by ACADIA Pharmaceuticals Inc. for \$53 million upfront and contingent payments of \$887 million
- Exelixis, Inc. in its exclusive clinical development and option agreement with Sairopa B.V. for a monoclonal antibody drug targeting cancer cells
- MorphoSys AG in its \$2.9 billion acquisition by Novartis AG and simultaneous sale of all worldwide rights to the antibody drug tafasitamab to Incyte Corporation
- Pfizer Inc. in connection with various research and development financing arrangements
- POINT Biopharma Global, Inc. in its \$1.4 billion acquisition by Eli Lilly and Company

Other Representative Transactions

- ByteDance Ltd. in connection with various matters related to the TikTok app
- Coty Inc. in its strategic partnership with KKR & Co. Inc., including a \$1 billion investment to be made in two tranches (\$750 million and \$250 million) in Coty through the sale of convertible preferred shares to KKR
- Dell Technologies Inc. in its \$4 billion sale of Boomi, Inc. to Francisco Partners and TPG Capital
- Massachusetts Mutual Life Insurance Company in the \$2.35 billion sale of its retirement plan business to Empower Retirement, LLC
- OceanSound Partners, LP in its strategic investment in Lynx Software Technologies and various other transactions
- Purolite Corporation in its \$3.7 billion sale to Ecolab Inc.
- Spotify Technology S.A. in its acquisition of Bill Simmons' The Ringer
- Tula Life, a probiotic skincare company, in its acquisition by Procter & Gamble